| Autor: |
Christopher Livia, Sara Inglis, Ruben Crespo‐Diaz, Skylar Rizzo, Ryan Mahlberg, Monique Bagwell, Matthew Hillestad, Satsuki Yamada, Dhivya Vadhana Meenakshi Siddharthan, Raman Deep Singh, Xing Li, D. Kent Arrell, Paul Stalboerger, Tyra Witt, Abdallah El Sabbagh, Munveer Rihal, Charanjit Rihal, Andre Terzic, Jozef Bartunek, Atta Behfar |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 9 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2047-9980 |
| DOI: |
10.1161/JAHA.123.032172 |
| Popis: |
Background The purpose of this study was to investigate a therapeutic approach targeting the inflammatory response and consequent remodeling from ischemic myocardial injury. Methods and Results Coronary thrombus aspirates were collected from patients at the time of ST‐segment–elevation myocardial infarction and subjected to array‐based proteome analysis. Clinically indistinguishable at myocardial infarction (MI), patients were stratified into vulnerable and resilient on the basis of 1‐year left ventricular ejection fraction and death. Network analysis from coronary aspirates revealed prioritization of tumor necrosis factor‐α signaling in patients with worse clinical outcomes. Infliximab, a tumor necrosis factor‐α inhibitor, was infused intravenously at reperfusion in a porcine MI model to assess whether infliximab‐mediated immune modulation impacts post‐MI injury. At 3 days after MI (n=7), infliximab infusion increased proregenerative M2 macrophages in the myocardial border zone as quantified by immunofluorescence (24.1%±23.3% in infliximab versus 9.29%±8.7% in sham; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text